Are oncoantigens suitable targets for anti-tumour therapy?

Nature Reviews Cancer

Volumn 7, Issue 9, 2007, Pages 707-713

  Cavallo, Federica ^a   Calogero, Raffaele Adolfo ^a   Forni, Guido ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD20 ANTIGEN; CD22 ANTIGEN; MUCIN 1; PROTEIN RET; SCATTER FACTOR RECEPTOR; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; CANCER CELL; CANCER GROWTH; CANCER STAGING; CARCINOGENESIS; CARCINOMA IN SITU; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DNA MICROARRAY; DRUG DESIGN; DRUG TARGETING; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HUMAN; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; DISEASE PROGRESSION; DRUG DESIGN; GENE EXPRESSION PROFILING; HUMANS; IMMUNE TOLERANCE; MICE; MICE, TRANSGENIC; MODELS, IMMUNOLOGICAL; NEOPLASMS;

EID: 34548283459     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2208     Document Type: Review

References (83)

1. Szabo, E. Selecting targets for cancer prevention: where do we go from here? Nature Rev. Cancer 6, 867-874 (2006).
2. Kalluri, R. & Zeisberg, M. Fibroblasts in cancer. Nature Rev. Cancer 6, 392-401 (2006).
3. Karre, K., Ljunggren, H. G., Piontek, G. & Kiessling, R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319, 675-678 (1986).
4. Bauer, S. et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285, 727-729 (1999).
5. Nolte-'t Hoen, E. N. et al. Increased surveillance of cells in mitosis by human NK cells suggests a novel strategy for limiting tumor growth and viral replication. Blood 109, 670-673 (2007).
6. Merlo, L. M., Pepper, J. W., Reid, B. J. & Maley, C. C. Cancer as an evolutionary and ecological process. Nature Rev. Cancer 6, 924-935 (2006).
7. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol. 3, 991-998 (2002).
8. Finn, O. J. Premalignant lesions as targets for cancer vaccines. J. Exp. Med. 198, 1623-1626 (2003).
9. Lollini, P. L., Cavallo, F., Nanni, P. & Forni, G. Vaccines for tumour prevention. Nature Rev. Cancer 6, 204-216 (2006).
10. Finn, O. J. Cancer vaccines: between the idea and the reality. Nature Rev. Immunol. 3, 630-641 (2003).
11. Lollini, P. L. & Forni, G. Cancer immunoprevention: tracking down persistent tumor antigens. Trends Immunol. 24, 62-66 (2003).
12. Nanni, P. et al. p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. Int. J. Cancer 87, 186-194 (2000).
13. Holmgren, L. et al. A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth. Proc. Natl Acad. Sci. USA 103, 9208-9213 (2006).
14. Ferrara, N., Mass, R. D., Campa, C. & Kim, R. Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu. Rev. Med. 58, 491-504 (2007).
15. Friedman, L. M. et al. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc. Natl Acad. Sci. USA 102, 1915-1920 (2005).
16. Nanni, P. et al. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J. Exp. Med. 194, 1195-1205 (2001).
17. Luo, W., Ko, E., Hsu, J. C., Wang, X. & Ferrone, S. Targeting melanoma cells with human high molecular weight-melanoma associated antigen-specific antibodies elicited by a peptide mimotope: functional effects. J. Immunol. 176, 6046-6054 (2006).
18. Yarden, Y. & Sliwkowski, M. X. Untangling the ErbB signalling network. Nature Rev. Mol. Cell Biol. 2, 127-137 (2001).
19. Boccaccio, C. & Comoglio, P. M. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nature Rev. Cancer 6, 637-645 (2006).
20. Zbuk, K. M. & Eng, C. Cancer phenomics: RET and PTEN as illustrative models. Nature Rev. Cancer 7, 35-45 (2007).
21. Pedersen, I. M., Buhl, A. M., Klausen, P., Geisler, C. H. & Jurlander, J. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 99, 1314-1319 (2002).
22. Gunawardana, C. G. & Diamandis, E. P. High throughput proteomic strategies for identifying tumour-associated antigens. Cancer Lett. 249, 110-119 (2007).
23. Preuss, K. D., Zwick, C., Bormann, C., Neumann, F. & Pfreundschuh, M. Analysis of the B-cell repertoire against antigens expressed by human neoplasms. Immunol. Rev. 188, 43-50 (2002).
24. Klade, C. S. Proteomics approaches towards antigen discovery and vaccine development. Curr. Opin. Mol. Ther. 4, 216-223 (2002).
25. Kreunin, P., Yoo, C., Urquidi, V., Lubman, D. M. & Goodison, S. Proteomic profiling identifies breast tumor metastasis-associated factors in an isogenic model. Proteomics 7, 299-312 (2007).
26. He, Y. D. Genomic approach to biomarker identification and its recent applications. Cancer Biomark. 2, 103-133 (2006).
27. Narayanan, R. Bioinformatics approaches to cancer gene discovery. Methods Mol. Biol. 360, 13-31 (2007).
28. Abate-Shen, C. A new generation of mouse models of cancer for translational research. Clin. Cancer Res. 12, 5274-5276 (2006).
29. Rangarajan, A. & Weinberg, R. A. Opinion: comparative biology of mouse versus human cells: modelling human cancer in mice. Nature Rev. Cancer 3, 952-959 (2003).
30. Greenman, C. et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153-158 (2007).
31. Weitzman, J. B. & Yaniv, M. Rebuilding the road to cancer. Nature 400, 401-402 (1999).
32. Pillai, R. S., Bhattacharyya, S. N. & Filipowicz, W. Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol. 17, 118-126 (2007).
33. Hossain, A., Kuo, M. T. & Saunders, G. F. Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol. Cell Biol. 26, 8191-8201 (2006).
34. Uhlen, M. et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol. Cell Proteomics 4, 1920-1932 (2005).
35. Cavallo, F. et al. An integrated approach of immunogenomics and bioinformatics to identify new Tumor Associated Antigens (TAA) for mammary cancer immunological prevention. BMC Bioinformatics 6 Suppl. 4, S7 (2005).
36. Barrett, T. et al. NCBI GEO: mining tens of millions of expression profiles - database and tools update. Nucleic Acids Res. 35, D760-D765 (2007).
37. Parkinson, H. et al. ArrayExpress-a public database of microarray experiments and gene expression profiles. Nucleic Acids Res. 35, D747-D750 (2007).
38. Michiels, S., Koscielny, S. & Hill, C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 365, 488-492 (2005).
39. Sims, A. H., Ong, K. R., Clarke, R. B. & Howell, A. High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic? Breast Cancer Res. 8, 214 (2006).
40. Lu, Y. et al. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med. 3, e467 (2006).
41. Mehra, R. et al. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res. 65, 11259-11264 (2005).
42. Miles, M. F. & Williams, R. W. Meta-analysis for microarray studies of the genetics of complex traits. Trends Biotechnol. 25, 45-47 (2007).
43. Hyatt, G. et al. Gene expression microarrays: glimpses of the immunological genome. Nature Immunol. 7, 686-691 (2006).
44. van 't Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
45. Miller, L. D. et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl Acad. Sci. USA 102, 13550-13555 (2005).
46. Pawitan, Y. et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 7, R953-R964 (2005).
47. Calogero, R., Cordero, F, Forni, G & Cavallo, F. Inflammatory component of mammary carcinogenesis in ErbB2 transgenic mice. Breast Cancer Res. (in the press).
48. Vlad, A. M., Kettel, J. C., Alajez, N. M., Carlos, C. A. & Finn, O. J. MUC1 immunobiology: from discovery to clinical applications. Adv. Immunol. 82, 249-293 (2004).
49. Carraway, K. L., 3rd, Funes, M., Workman, H. C. & Sweeney, C. Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways. Curr. Top. Dev. Biol. 78, 1-22 (2007).
50. Wei, X., Xu, H. & Kufe, D. Human mucin 1 oncoprotein represses transcription of the p53 tumor suppressor gene. Cancer Res. 67, 1853-1858 (2007).
51. Thompson, E. J. et al. Tyrosines in the MUC1 cytoplasmic tail modulate transcription via the extracellular signal-regulated kinase 1/2 and nuclear factor-κB pathways. Mol. Cancer Res. 4, 489-497 (2006).
52. Singh, P. K. & Hollingsworth, M. A. Cell surface-associated mucins in signal transduction. Trends Cell Biol. 16, 467-476 (2006).
53. Kohlgraf, K. G. et al. Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. Cancer Res. 63, 5011-5020 (2003).
54. Ambrosino, E. et al. Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res. 66, 7734-7740 (2006).
55. Rolla, S. et al. Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. J. Immunol. 177, 7626-7633 (2006).
56. Sakaguchi, N. et al. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 426, 454-460 (2003).
57. Disis, M. L. et al. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J. Clin. Oncol. 15, 3363-3367 (1997).
58. Al-Batran, S. E. et al. Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma. Cancer Res. 65, 3937-3941 (2005).
59. Ohlen, C. et al. CD8(+) T cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector function. J. Exp. Med. 195, 1407-1418 (2002).
60. Nanni, P. et al. Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent. J. Immunol. 173, 2288-2296 (2004).
61. Park, J. M. et al. Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas. J. Immunol. 174, 4228-4236 (2005).
62. Imai, K. & Takaoka, A. Comparing antibody and small-molecule therapies for cancer. Nature Rev. Cancer 6, 714-727 (2006).
63. Terabe, M. et al. Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198, 1741-1752 (2003).
64. Bronte, V. & Zanovello, P. Regulation of immune responses by L-arginine metabolism. Nature Rev. Immunol. 5, 641-654 (2005).
65. Gallina, G. et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J. Clin. Invest. 116, 2777-2790 (2006).
66. Lustgarten, J., Dominguez, A. L. & Cuadros, C. The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity. Eur. J. Immunol. 34, 752-761 (2004).
67. Cavallo, F., Offringa, R., van der Burg, S. H., Forni, G. & Melief, C. J. Vaccination for treatment and prevention of cancer in animal models. Adv. Immunol. 90, 175-213 (2006).
68. Quaglino, E. et al. Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res. 64, 2858-2864 (2004).
69. Quaglino, E. et al. Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. J. Clin. Invest. 113, 709-717 (2004).
70. Haber, D. A. & Settleman, J. Cancer: drivers and passengers. Nature 446, 145-146 (2007).
71. Sjoblom, T. et al. The consensus coding sequences of human breast and colorectal cancers. Science 314, 268-274 (2006).
72. Pannellini, T. et al. Timely DNA vaccine combined with systemic IL-12 prevents parotid carcinomas before a dominant-negative p53 makes their growth independent of HER-2/neu expression. J. Immunol. 176, 7695-7703 (2006).
73. Dorrell, M. I., Aguilar, E., Scheppke, L., Barnett, F. H. & Friedlander, M. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc. Natl Acad. Sci. USA 104, 967-972 (2007).
74. Emens, L. A. Roadmap to a better therapeutic tumor vaccine. Int. Rev. Immunol. 25, 415-443 (2006).
75. Lu, H., Knutson, K. L., Gad, E. & Disis, M. L. The tumor antigen repertoire identified in tumor-bearing Neu transgenic mice predicts human tumor antigens. Cancer Res. 66, 9754-9761 (2006).
76. Pannellini, T., Forni, G. & Musiani, P. Immunobiology of her-2/neu transgenic mice. Breast Dis. 20, 33-42 (2004).
77. Astolfi, A. et al. Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. Am. J. Pathol. 166,1205-1216 (2005).
78. Astolfi, A. et al. Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario. Cancer Immunol. Immunother. 54, 599-610 (2005).
79. Melani, C., Chiodoni, C., Forni, G. & Colombo, M. P. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 102, 2138-2145 (2003).
80. Garber, K. New insights into oncogene addiction found. J. Natl Cancer Inst. 99, 264-265, 269 (2007).
81. Cappello, P. et al. LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. Cancer Res. 63, 2518-25 (2003).
82. Ercolini, A. M. et al. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J. Exp. Med. 201, 1591-1602 (2005).
83. Albini, A. & Sporn, M. B. The tumour microenvironment as a target for chemoprevention. Nature Rev. Cancer 7, 139-147 (2007).